Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the ...
Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis ® ...
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been ...
About TNX-1700 TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed ...
Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...
Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting ...
The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond ...
Developed within the clinical and educational framework of Caring for the Body, PLLC, Re-Think Aging combines evidence-based medicine, functional and longevity science, and whole-person care to ...
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- ...
One abstract will include new biomarker and immunogenicity data for cancer vaccine EVX-01. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results